Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine
reuptake inhibitor (SNRI). This study will investigate the safety, efficacy, and tolerability
of DVS SR versus escitalopram in women with major depressive disorder (MDD) who are
postmenopausal.